SABS Earnings Date: Nov 13, 2026 (Estimated) — SAB Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is SABS's next earnings date?
SAB Biotherapeutics, Inc. (SABS) is expected to report earnings on Friday, November 13, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.27 on revenue of $125,000.
How did SABS do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), SAB Biotherapeutics, Inc. posted EPS of -$0.28 versus the -$0.28 estimate, a beat of 0.0%. Revenue was $0 against a $125,000 estimate. The stock's 1-day post-earnings move was +2.1%.
How much does SABS stock move after earnings?
SABS beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.9% (up or down) in the day after earnings.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.28 | -0.28 | +0.00% | $0 | ✅ Beat | +2.12% | +0.80% | -1.33% |
| 2026-05-12 | Q1 2026 | -0.21 | -0.35 | -66.67% | $0 | ❌ Miss | -2.69% | -4.30% | -11.02% |
| 2026-03-09 | Q4 2025 | -0.33 | -0.46 | -39.39% | $0 | ❌ Miss | +6.77% | +2.60% | -2.86% |
| 2025-11-13 | Q3 2025 | -0.51 | -0.21 | +58.82% | $0 | ✅ Beat | +4.52% | +22.58% | +29.03% |
| 2025-03-28 | Q4 2024 | -1.21 | -1.23 | — | $114,698 | ❌ Miss | -8.11% | -23.65% | +11.82% |
| 2024-05-20 | Q1 2024 | -0.46 | -0.54 | -17.39% | $944,575 | ❌ Miss | -15.65% | -21.16% | -19.71% |
| 2024-03-29 | Q4 2023 | -0.62 | -3.84 | -519.35% | $305,011 | ❌ Miss | -5.51% | -4.41% | -7.71% |
| 2023-11-13 | Q3 2023 | -1.20 | -1.00 | +16.67% | $1.3M | ✅ Beat | -2.15% | -10.34% | -13.99% |
Showing last 8 quarters.